logo
  

Host Hotels & Resorts Acquires Four Seasons Resort Orlando At Walt Disney World Resort For $610 Mln

Host Hotels & Resorts, Inc. (HST) Tuesday said it has acquired the 444-room Four Seasons Resort Orlando at Walt Disney World Resort for about $610 million in cash.

CEO James Risoleo said, "Four Seasons Resort Orlando at Walt Disney World Resort is a truly iconic and irreplaceable property that is well-positioned to benefit from significant demand as the pandemic subsides and the 18-month celebration of Walt Disney World's 50th anniversary begins in October. A strong market leader with a 2019 RevPAR Index over 215, this resort is now Host Hotels' highest-ranked property based on 2019 RevPAR and Total RevPAR, and fifth highest based on EBITDA per key."

The company acquired the resort for $610 million or $1.4 million per key, representing a 4.7% capitalization rate, 16.8x EBITDA multiple based on 2019 results.

The resort generated RevPAR of $561, total RevPAR of $923 and EBITDA/key of $81,5002, which represents 90% growth since 2016.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
RELATED NEWS
Follow RTT